Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K current report with the SEC on May 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Donn Casale appointed President effective expected June 1, 2026, succeeding CEO Richard Lowenthal in the role.
ARS Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Donn Casale appointed President effective expected June 1, 2026, succeeding CEO Richard Lowenthal in the role
- Casale brings over 25 years of biopharmaceutical experience, including Chief Commercial Officer at Dynavax since January 2023
- Annual compensation includes $575,000 base salary and 45% discretionary bonus eligibility
- $6 million stock option grant, with 25% vesting after one year and remaining shares monthly over 36 months
- C-suite severance and change-in-control protections, with limited option acceleration during Casale’s first year
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARS Pharmaceuticals, Inc. 8-K filings
Get the next SPRY 8-K as it lands
Follow SPRY for push alerts, or ask the research agent what this filing means.